secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001628280-25-033302
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve 4.75M share increase to equity plan and new ESPP at annual meeting
--------------------------------------------------------------------------------

- Amendment to 2017 Equity Incentive Plan adds 4,750,000 shares; approved by 53,046,229 votes for.
- Employee Stock Purchase Plan approved: 650,000 shares authorized, purchased at 85% of lower of grant/ purchase price.
- All eight director nominees elected; Steven Rubin received 12.4M withheld votes, others largely unanimous.
- Crowe LLP ratified as independent auditor for FY2025 with 63.4M votes for.
- Advisory say-on-pay proposal passed with 54.9M for vs 1.2M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025033302/0001628280-25-033302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025033302/cdxc-20250624.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-033302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer